Shares of IlluminaILMN have risen 44.8% over the past year, reflecting strong momentum. The stock has outpaced the industry’s ...
Dublin, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The "Next Generation Sequencing Market Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and ...
Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.
(MENAFN- GlobeNewsWire - Nasdaq) The Next-Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include ...
Element Biosciences is going toe-to-toe with gene-sequencing giant Illumina, unveiling a device that can read DNA for half the price of the industry leader’s technology. On Thursday, Element ...
Why Illumina (ILMN) Is Up 14.3% After Launching TruPath Genome And Expanding Rare-Disease Sequencing
In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome solution and expanded clinical sequencing services, including supporting Florida State University’s new pediatric rare ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 3:10 PM ESTCompany ParticipantsJacob Thaysen - CEO, Interim Chief ...
AGBT is also, increasingly, a showcase for instruments for spatial biology, a fast-growing field that involves pinpointing the location of RNA and protein molecules en masse. Tarbox calls the meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results